Skip to content
DraconiticResearch
Search Sources API
194,161 studies31 sourcesUpdated 8 min ago
Peer-reviewedCC BY-NC 4.0Asian Pacific Journal of Cancer Prevention : APJCP

Impact of Depiction of Brown Adipose Tissue (BAT) in Baseline FDG PET/CT on Progression-free Survival in Lymphoma Patients

  • Maseeh Uz Zaman1
  • Nosheen Fatima1,2
  • Sidra Zaman3
  • Anwar Ahmed1
  • Uzair Ahmed4
  • Minhaj Ahmed4
  • Areeba Zaman5
  • Rabiya Fatima Hashmi6
6 affiliations
  1. 1Department of Radiology, Aga Khan University Hospital, Karachi, Pakistan.
  2. 2Department of NM and Theranostic, Dow University of Health Sciences, Karachi, Pakistan.
  3. 3Department of Medicine, MedStar Medical Centre, Maryland, USA.
  4. 4Students Aga Khan University Medical College, Karachi, Pakistan.
  5. 5Department of Medicine, Integris Hospital, Oklahoma, USA.
  6. 6Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan.
Read full textPDFDOICite

Abstract

Introduction:: Brown adipose tissue (BAT) activity seen on 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) has been increasingly recognized as a potential biomarker in various cancers, including lymphomas. The aim of this study was to investigate the correlation between posttreatment survival outcomes and BAT activity depicted in baseline FDG PET/CT scans in lymphoma patients.

Material and Method:: This retrospective study was conducted at the PET/CT Section of the Department of Radiology, Aga Khan University Hospital, Karachi, Pakistan (2019–2025). The study was granted exemption by the Ethical Review Committee (2024-10630-31016). Patients with lymphoma (Hodgkin’s and non-Hodgkin’s; HL; NHL) whose baseline FDG PET/CT revealed BAT activation were selected. FDG PET/CT scan was acquired using a standardized protocol adopted from the European Association of Nuclear Medicine Guidelines (2015). These patients were followed for a mean of 03 years (range 15–36 months) for survival outcome (progression-free survival; PFS).

Results:: During the study period, 259 patients with lymphomas (96 HL and 163 HL) who had baseline FDG PET/CT were selected. The cohort included 75% males (n = 194) and 25% females (n = 65), with a median age of 58 years (range: 03-80). BAT activation was identified in 27% of patients (n = 69). A significant association was observed between BAT activation and higher 3-year PFS, with activated BAT patients achieving a survival rate of 78% compared to 58% in those without activation (p < 0.05).

Conclusion:: Lymphoma patients with activated BAT depicted in their baseline FDG PET/CTs showed longer progression-free survival than those without. This study also emphasizes the need for further evaluation of BAT’s role in metabolism, tumor microenvironment, and long-term prognosis in patients with lymphomas.

Related

  1. Associations of Subcutaneous and Visceral Fat Areas with Progression-Free Survival in Patients with Diffuse Large B-Cell Lymphoma.
    Jiun-Hung Geng, Chien-Hsiang Chang, Yi-Chang Liu +9
    International journal of medical sciencesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Baseline Tumor Transcriptional Features and Event-Free Survival After Anti-CD19 CAR T-Cell Therapy with Axicabtagene Ciloleucel in Large B-Cell Lymphoma: An Exploratory Reanalysis of the Randomized ZUMA-7 Trial
    Jean Silva de Souza Resende, Igor Samesima Giner, Maria Gabriela Custodio de Figueiredo +4
    Medical sciences (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Baseline Spleen Volume is Independently Associated With Survival After CD19-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
    Lucas Brehm, Philipp Schindler, Christian Römer +11
    Hematological oncologyPeer-reviewedCC BYFull textOncologyEurope PMCPMC
  4. Baseline 25-hydroxyvitamin D and progression-free survival in de novo metastatic hormone-sensitive prostate cancer: prognostic model development and external validation.
    Galip Can Uyar, Kadriye Başkurt, Orhun Akdoğan +8
    The oncologistPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Socioeconomic deprivation does not affect survival outcomes in patients with mantle cell lymphoma: evidence from a German nationwide study.
    Susanne von Kroge, Sabrina Klotz, Hanna Walk +5
    Blood cancer journalPeer-reviewedCC BYFull textGeneral medicineEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{zaman2026impact,
  title = {{Impact of Depiction of Brown Adipose Tissue (BAT) in Baseline FDG PET/CT on Progression-free Survival in Lymphoma Patients}},
  author = {Maseeh Uz Zaman and Nosheen Fatima and Sidra Zaman and Anwar Ahmed and Uzair Ahmed and Minhaj Ahmed and Areeba Zaman and Rabiya Fatima Hashmi},
  journal = {Asian Pacific Journal of Cancer Prevention : APJCP},
  year = {2026},
  month = jun,
  doi = {10.31557/apjcp.2026.27.6.2061},
  url = {https://doi.org/10.31557/apjcp.2026.27.6.2061},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Impact of Depiction of Brown Adipose Tissue (BAT) in Baseline FDG PET/CT on Progression-free Survival in Lymphoma Patients
AU  - Maseeh Uz Zaman
AU  - Nosheen Fatima
AU  - Sidra Zaman
AU  - Anwar Ahmed
AU  - Uzair Ahmed
AU  - Minhaj Ahmed
AU  - Areeba Zaman
AU  - Rabiya Fatima Hashmi
PY  - 2026
DA  - 2026/06/18
JO  - Asian Pacific Journal of Cancer Prevention : APJCP
DO  - 10.31557/apjcp.2026.27.6.2061
UR  - https://doi.org/10.31557/apjcp.2026.27.6.2061
AB  - Introduction:: Brown adipose tissue (BAT) activity seen on 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) has been increasingly recognized as a potential biomarker in various cancers, including lymphomas. The aim of this study was to investigate the correlation between posttreatment survival outcomes and BAT activity depicted in baseline FDG PET/CT scans in lymphoma patients.  Material and Method:: This retrospective study was conducted at the PET/CT Section of the Department of Radiology, Aga Khan University Hospital, Karachi, Pakistan (2019–2025). The study was granted exemption by the Ethical Review Committee (2024-10630-31016). Patients with lymphoma (Hodgkin’s and non-Hodgkin’s; HL; NHL) whose baseline FDG PET/CT revealed BAT activation were selected. FDG PET/CT scan was acquired using a standardized protocol adopted from the European Association of Nuclear Medicine Guidelines (2015). These patients were followed for a mean of 03 years (range 15–36 months) for survival outcome (progression-free survival; PFS).  Results:: During the study period, 259 patients with lymphomas (96 HL and 163 HL) who had baseline FDG PET/CT were selected. The cohort included 75% males (n = 194) and 25% females (n = 65), with a median age of 58 years (range: 03-80). BAT activation was identified in 27% of patients (n = 69). A significant association was observed between BAT activation and higher 3-year PFS, with activated BAT patients achieving a survival rate of 78% compared to 58% in those without activation (p < 0.05).  Conclusion:: Lymphoma patients with activated BAT depicted in their baseline FDG PET/CTs showed longer progression-free survival than those without. This study also emphasizes the need for further evaluation of BAT’s role in metabolism, tumor microenvironment, and long-term prognosis in patients with lymphomas.
SN  - 1513-7368
SN  - 2476-762X
ER  -